3SBio's (HKG:1530) unit Shenyang Sunshine Pharmaceutical will obtain the commercialization rights for HER2 ADC drug DB-1303 from Duality Biologics (Shanghai) for various indications in China, Hong Kong, and Macau, a Monday Hong Kong bourse filing said.
Duality Biologics is a clinical-stage innovative biopharmaceutical company mainly engaged in the research and development of antibody-drug conjugates therapeutic agents for the treatment of patients with cancer or autoimmune diseases.
HER2, or Human Epidermal Growth Factor Receptor 2, is a protein that can be found on the surface of some cancer cells.
DB-1303 is designed to treat cancers that have high levels of HER2 expression, such as certain types of breast, gastric, and endometrial cancers. The drug combines an anti-HER2 monoclonal antibody with a topoisomerase I inhibitor, which helps to disrupt the cancer cells' DNA and inhibit their growth.
Shenyang Sunshine will make upfront fees and research, development, and sales milestone payments as part of the cooperation agreement.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。